Drug Profile
Research programme: metabotropic glutamate receptor modulators - Prexton Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer Prexton Therapeutics
- Class
- Mechanism of Action Metabotropic glutamate receptor 3 modulators; Metabotropic glutamate receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in Spain
- 30 Jul 2012 Early research in Parkinson's disease in Spain (unspecified route)